These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 20034872)

  • 1. [Targeting KRAS pathway in NSCLC therapy].
    Le Moulec S; Loriot Y; Soria JC
    Bull Cancer; 2009 Dec; 96 Suppl():S69-74. PubMed ID: 20034872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Targeting the RAS signalling pathway in cancer].
    Mansi L; Viel E; Curtit E; Medioni J; Le Tourneau C
    Bull Cancer; 2011 Oct; 98(9):1019-28. PubMed ID: 21715253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.
    Kelly RJ; Rajan A; Force J; Lopez-Chavez A; Keen C; Cao L; Yu Y; Choyke P; Turkbey B; Raffeld M; Xi L; Steinberg SM; Wright JJ; Kummar S; Gutierrez M; Giaccone G
    Clin Cancer Res; 2011 Mar; 17(5):1190-9. PubMed ID: 21224376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report.
    Smit EF; Dingemans AM; Thunnissen FB; Hochstenbach MM; van Suylen RJ; Postmus PE
    J Thorac Oncol; 2010 May; 5(5):719-20. PubMed ID: 20421765
    [No Abstract]   [Full Text] [Related]  

  • 5. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
    Takezawa K; Okamoto I; Yonesaka K; Hatashita E; Yamada Y; Fukuoka M; Nakagawa K
    Cancer Res; 2009 Aug; 69(16):6515-21. PubMed ID: 19638574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.
    Steelman LS; Franklin RA; Abrams SL; Chappell W; Kempf CR; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo P; Ruvolo V; Evangelisti C; Martelli AM; McCubrey JA
    Leukemia; 2011 Jul; 25(7):1080-94. PubMed ID: 21494257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF signaling and targeted therapies in melanoma.
    Dhomen N; Marais R
    Hematol Oncol Clin North Am; 2009 Jun; 23(3):529-45, ix. PubMed ID: 19464601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Focus on targeting the Ras-MAPK pathway: the Mek inhibitors].
    Baldini C; Duchemann B; Hollebecque A; Routier É; Varga A; Gazzah A; Bahleda R; Besse B; Soria JC; Massard C
    Bull Cancer; 2012 Sep; 99(9):865-74. PubMed ID: 25471668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NSCLC drug targets acquire new visibility.
    Friedrich MJ
    J Natl Cancer Inst; 2011 Mar; 103(5):366-7. PubMed ID: 21357596
    [No Abstract]   [Full Text] [Related]  

  • 10. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
    Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
    Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells.
    Lee HY; Moon H; Chun KH; Chang YS; Hassan K; Ji L; Lotan R; Khuri FR; Hong WK
    J Natl Cancer Inst; 2004 Oct; 96(20):1536-48. PubMed ID: 15494604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RAF and MEK Inhibitors in Non-Small Cell Lung Cancer.
    Adamopoulos C; Papavassiliou KA; Poulikakos PI; Papavassiliou AG
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
    Gridelli C; Maione P; Del Gaizo F; Colantuoni G; Guerriero C; Ferrara C; Nicolella D; Comunale D; De Vita A; Rossi A
    Oncologist; 2007 Feb; 12(2):191-200. PubMed ID: 17296815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. K-ras as a target for lung cancer therapy.
    Adjei AA
    J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S160-3. PubMed ID: 18520303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach.
    Yoon YK; Kim HP; Han SW; Oh DY; Im SA; Bang YJ; Kim TY
    Mol Carcinog; 2010 Apr; 49(4):353-62. PubMed ID: 20358631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel mitogen-activated protein kinase kinase inhibitors.
    Chapman MS; Miner JN
    Expert Opin Investig Drugs; 2011 Feb; 20(2):209-20. PubMed ID: 21235429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer.
    Metro G; Chiari R; Baldi A; De Angelis V; Minotti V; Crinò L
    Future Oncol; 2013 Feb; 9(2):167-77. PubMed ID: 23414467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway.
    Wong KK
    Recent Pat Anticancer Drug Discov; 2009 Jan; 4(1):28-35. PubMed ID: 19149686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor flare after start of RAF inhibition in KRAS mutated NSCLC: a case report.
    Mellema WW; Burgers SA; Smit EF
    Lung Cancer; 2015 Feb; 87(2):201-3. PubMed ID: 25488861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib.
    Caiola E; Frapolli R; Tomanelli M; Valerio R; Iezzi A; Garassino MC; Broggini M; Marabese M
    Sci Rep; 2018 Jan; 8(1):948. PubMed ID: 29343688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.